Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer
Abstract Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in man...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-01-01
|
| Series: | Insights into Imaging |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13244-024-01884-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559343358541824 |
|---|---|
| author | Yuki Arita Thomas C. Kwee Oguz Akin Keisuke Shigeta Ramesh Paudyal Christian Roest Ryo Ueda Alfonso Lema-Dopico Sunny Nalavenkata Lisa Ruby Noam Nissan Hiromi Edo Soichiro Yoshida Amita Shukla-Dave Lawrence H. Schwartz |
| author_facet | Yuki Arita Thomas C. Kwee Oguz Akin Keisuke Shigeta Ramesh Paudyal Christian Roest Ryo Ueda Alfonso Lema-Dopico Sunny Nalavenkata Lisa Ruby Noam Nissan Hiromi Edo Soichiro Yoshida Amita Shukla-Dave Lawrence H. Schwartz |
| author_sort | Yuki Arita |
| collection | DOAJ |
| description | Abstract Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting. The Vesical Imaging Reporting and Data System (VI-RADS), a multiparametric MRI (mpMRI)-based consensus reporting platform, allows for standardized preoperative muscle invasion assessment in BCa with proven diagnostic accuracy. However, post-treatment assessment using VI-RADS is challenging because of anatomical changes, especially in the interpretation of the muscle layer. MRI techniques that provide tumor tissue physiological information, including diffusion-weighted (DW)- and dynamic contrast-enhanced (DCE)-MRI, combined with derived quantitative imaging biomarkers (QIBs), may potentially overcome the limitations of BCa evaluation when predominantly focusing on anatomic changes at MRI, particularly in the therapy response setting. Delta-radiomics, which encompasses the assessment of changes (Δ) in image features extracted from mpMRI data, has the potential to monitor treatment response. In comparison to the current Response Evaluation Criteria in Solid Tumors (RECIST), QIBs and mpMRI-based radiomics, in combination with artificial intelligence (AI)-based image analysis, may potentially allow for earlier identification of therapy-induced tumor changes. This review provides an update on the potential of QIBs and mpMRI-based radiomics and discusses the future applications of AI in BCa management, particularly in assessing treatment response. Critical relevance statement Incorporating mpMRI-based quantitative imaging biomarkers, radiomics, and artificial intelligence into bladder cancer management has the potential to enhance treatment response assessment and prognosis prediction. Key Points Quantitative imaging biomarkers (QIBs) from mpMRI and radiomics can outperform RECIST for bladder cancer treatments. AI improves mpMRI segmentation and enhances radiomics feature extraction effectively. Predictive models integrate imaging biomarkers and clinical data using AI tools. Multicenter studies with strict criteria validate radiomics and QIBs clinically. Consistent mpMRI and AI applications need reliable validation in clinical practice. Graphical Abstract |
| format | Article |
| id | doaj-art-22fc633e71434220bc2a197145fe7078 |
| institution | Kabale University |
| issn | 1869-4101 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Insights into Imaging |
| spelling | doaj-art-22fc633e71434220bc2a197145fe70782025-01-05T12:32:35ZengSpringerOpenInsights into Imaging1869-41012025-01-0116112110.1186/s13244-024-01884-5Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancerYuki Arita0Thomas C. Kwee1Oguz Akin2Keisuke Shigeta3Ramesh Paudyal4Christian Roest5Ryo Ueda6Alfonso Lema-Dopico7Sunny Nalavenkata8Lisa Ruby9Noam Nissan10Hiromi Edo11Soichiro Yoshida12Amita Shukla-Dave13Lawrence H. Schwartz14Department of Radiology, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center GroningenDepartment of Radiology, Memorial Sloan Kettering Cancer CenterDana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Medical Physics, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center GroningenOffice of Radiation Technology, Keio University HospitalDepartment of Medical Physics, Memorial Sloan Kettering Cancer CenterDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, National Defense Medical CollegeDepartment of Urology, Institute of Science TokyoDepartment of Radiology, Memorial Sloan Kettering Cancer CenterDepartment of Radiology, Memorial Sloan Kettering Cancer CenterAbstract Bladder cancer is the 10th most common and 13th most deadly cancer worldwide, with urothelial carcinomas being the most common type. Distinguishing between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is essential due to significant differences in management and prognosis. MRI may play an important diagnostic role in this setting. The Vesical Imaging Reporting and Data System (VI-RADS), a multiparametric MRI (mpMRI)-based consensus reporting platform, allows for standardized preoperative muscle invasion assessment in BCa with proven diagnostic accuracy. However, post-treatment assessment using VI-RADS is challenging because of anatomical changes, especially in the interpretation of the muscle layer. MRI techniques that provide tumor tissue physiological information, including diffusion-weighted (DW)- and dynamic contrast-enhanced (DCE)-MRI, combined with derived quantitative imaging biomarkers (QIBs), may potentially overcome the limitations of BCa evaluation when predominantly focusing on anatomic changes at MRI, particularly in the therapy response setting. Delta-radiomics, which encompasses the assessment of changes (Δ) in image features extracted from mpMRI data, has the potential to monitor treatment response. In comparison to the current Response Evaluation Criteria in Solid Tumors (RECIST), QIBs and mpMRI-based radiomics, in combination with artificial intelligence (AI)-based image analysis, may potentially allow for earlier identification of therapy-induced tumor changes. This review provides an update on the potential of QIBs and mpMRI-based radiomics and discusses the future applications of AI in BCa management, particularly in assessing treatment response. Critical relevance statement Incorporating mpMRI-based quantitative imaging biomarkers, radiomics, and artificial intelligence into bladder cancer management has the potential to enhance treatment response assessment and prognosis prediction. Key Points Quantitative imaging biomarkers (QIBs) from mpMRI and radiomics can outperform RECIST for bladder cancer treatments. AI improves mpMRI segmentation and enhances radiomics feature extraction effectively. Predictive models integrate imaging biomarkers and clinical data using AI tools. Multicenter studies with strict criteria validate radiomics and QIBs clinically. Consistent mpMRI and AI applications need reliable validation in clinical practice. Graphical Abstracthttps://doi.org/10.1186/s13244-024-01884-5Artificial intelligenceBiomarkerMultiparametric magnetic resonance imagingTreatment responseUrinary bladder neoplasm |
| spellingShingle | Yuki Arita Thomas C. Kwee Oguz Akin Keisuke Shigeta Ramesh Paudyal Christian Roest Ryo Ueda Alfonso Lema-Dopico Sunny Nalavenkata Lisa Ruby Noam Nissan Hiromi Edo Soichiro Yoshida Amita Shukla-Dave Lawrence H. Schwartz Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer Insights into Imaging Artificial intelligence Biomarker Multiparametric magnetic resonance imaging Treatment response Urinary bladder neoplasm |
| title | Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| title_full | Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| title_fullStr | Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| title_full_unstemmed | Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| title_short | Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| title_sort | multiparametric mri and artificial intelligence in predicting and monitoring treatment response in bladder cancer |
| topic | Artificial intelligence Biomarker Multiparametric magnetic resonance imaging Treatment response Urinary bladder neoplasm |
| url | https://doi.org/10.1186/s13244-024-01884-5 |
| work_keys_str_mv | AT yukiarita multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT thomasckwee multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT oguzakin multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT keisukeshigeta multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT rameshpaudyal multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT christianroest multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT ryoueda multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT alfonsolemadopico multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT sunnynalavenkata multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT lisaruby multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT noamnissan multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT hiromiedo multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT soichiroyoshida multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT amitashukladave multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer AT lawrencehschwartz multiparametricmriandartificialintelligenceinpredictingandmonitoringtreatmentresponseinbladdercancer |